MX370905B - Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos. - Google Patents

Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.

Info

Publication number
MX370905B
MX370905B MX2014009830A MX2014009830A MX370905B MX 370905 B MX370905 B MX 370905B MX 2014009830 A MX2014009830 A MX 2014009830A MX 2014009830 A MX2014009830 A MX 2014009830A MX 370905 B MX370905 B MX 370905B
Authority
MX
Mexico
Prior art keywords
weakly basic
drug delivery
delivery systems
solid solutions
basic drugs
Prior art date
Application number
MX2014009830A
Other languages
English (en)
Inventor
Lai Jin-Wang
Mapelli Luigi
Boltri Luigi
Venkatesh Gopi
Colombo Italo
Flabiani Flavio
Original Assignee
Adare Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adare Pharmaceuticals Inc filed Critical Adare Pharmaceuticals Inc
Publication of MX370905B publication Critical patent/MX370905B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está dirigida a las composiciones farmacéuticas y a las formas de dosis que comprenden esferas de TPR, en donde las esferas de TPR comprenden una dispersión sólida de al menos un ingrediente farmacéutico activo en al menos un polímero aumentador de la solubilidad, y un recubrimiento de TPR que comprende un polímero insoluble en agua y un polímero entérico, en donde el ingrediente farmacéutico activo comprende un ingrediente farmacéutico activo débilmente básico, que tiene una solubilidad no mayor de 100 µg/ml a pH 6.8.
MX2014009830A 2006-08-31 2007-08-29 Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos. MX370905B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84189306P 2006-08-31 2006-08-31
US84176006P 2006-08-31 2006-08-31
PCT/US2007/077153 WO2008027993A2 (en) 2006-08-31 2007-08-29 Drug delivery systems comprising solid solutions of weakly basic drugs

Publications (1)

Publication Number Publication Date
MX370905B true MX370905B (es) 2020-01-09

Family

ID=39136847

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009002166A MX2009002166A (es) 2006-08-31 2007-08-29 Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.
MX2014009830A MX370905B (es) 2006-08-31 2007-08-29 Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009002166A MX2009002166A (es) 2006-08-31 2007-08-29 Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.

Country Status (12)

Country Link
US (3) US20080069878A1 (es)
EP (1) EP2056792B1 (es)
JP (2) JP5513113B2 (es)
KR (2) KR101468053B1 (es)
BR (1) BRPI0716196A2 (es)
CA (1) CA2661683C (es)
ES (1) ES2953390T3 (es)
IL (1) IL197204A0 (es)
MX (2) MX2009002166A (es)
NZ (1) NZ575171A (es)
RU (1) RU2434630C2 (es)
WO (1) WO2008027993A2 (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
ES2953390T3 (es) 2006-08-31 2023-11-10 Adare Pharmaceuticals Inc Sistemas de administración de fármacos que comprenden disoluciones sólidas de fármacos débilmente básicos
CA2711475A1 (en) * 2008-01-10 2009-07-16 Evonik Roehm Gmbh Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
US9011907B2 (en) 2008-01-10 2015-04-21 Evonik Röhm Gmbh Coated pharmaceutical or nutraceutical preparation with enhanced pulsed active substance release
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
EP2282779B1 (en) 2008-04-29 2013-03-13 Pharnext New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
MX2010012080A (es) * 2008-05-05 2011-04-11 Univ Winthrop Hospital Metodo para mejorar el perfil de riesgo cardiovascular de los inhibidores de cox.
WO2009137067A1 (en) * 2008-05-08 2009-11-12 Supernus Pharmaceuticals Inc. Controlled release formulations of alprazolam
FR2938432B1 (fr) * 2008-11-14 2011-05-20 Debregeas Et Associes Pharma Nouveau procede de preparation de granules de principes actifs, et granules tels qu'obtenus
CN104208714A (zh) * 2008-11-18 2014-12-17 Ucb医药有限公司 含有2-氧代-1-吡咯烷衍生物的延长释放制剂
PT2358361T (pt) * 2008-11-18 2016-11-18 Ucb Biopharma Sprl Formulações de libertação prolongada compreendendo um derivado de 2-oxo-1-pirrolidina
EP2374460A4 (en) * 2008-12-12 2013-08-21 Rhein Siegfried Sa De Cv SILDENAFIL COMPOSITION WITH PULSED RELEASE AND METHOD FOR PRODUCING THIS COMPOSITION
CA3014688A1 (en) 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of aggression, irritability, or impulsivity
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
DK2391349T3 (da) * 2009-01-29 2014-11-03 Ucb Pharma Sa Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
CA2753444A1 (en) * 2009-02-23 2010-08-26 Gopi Venkatesh Controlled-release compositions comprising a proton pump inhibitor
CA2753416A1 (en) * 2009-02-23 2010-08-26 Gopi Venkatesh Controlled release compositions comprising anti-cholinergic drugs
MX2011010621A (es) * 2009-04-09 2012-01-30 Alkermes Pharma Ireland Ltd Composiciones de clozapina de liberacion controlada.
WO2011032916A1 (de) 2009-09-17 2011-03-24 Basf Se Mit wirkstoffhaltigen überzügen beschichtete pellets
FR2951378B1 (fr) * 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
BR112012012999A2 (pt) 2009-11-30 2019-04-02 Aptalis Pharmatech Inc Composição farmacêutica, e composição de tablete de desintegração oral (odt) outablete de dispersão rápida (rdt)
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
US20110256218A1 (en) * 2010-01-04 2011-10-20 Eurand, Inc. Controlled release compositions comprising meclizine or related piperazine derivatives
US20110212171A1 (en) * 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
DE102010005124A1 (de) * 2010-01-19 2012-03-01 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung umfassend Lercanidipin
US8748472B2 (en) 2010-03-31 2014-06-10 Supernus Pharmaceuticals, Inc. Stabilized formulations of CNS compounds
WO2011135430A1 (en) * 2010-04-29 2011-11-03 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
AU2011256928A1 (en) * 2010-05-24 2012-12-20 Lupin Limited Extended release formulation of pramipexole
KR101828630B1 (ko) * 2010-07-09 2018-02-12 데이진 화-마 가부시키가이샤 구강 내 붕괴 정제
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
CN102440971A (zh) * 2010-10-15 2012-05-09 重庆市力扬医药开发有限公司 伊潘立酮口腔崩解片
CN108969490A (zh) 2010-12-02 2018-12-11 艾戴尔医药公司 快速分散颗粒、口腔崩解片以及方法
CN102614140B (zh) * 2011-01-26 2015-11-25 浙江九洲药物科技有限公司 伊潘立酮口崩片及其制备方法
WO2012123963A2 (en) * 2011-02-24 2012-09-20 Megafine Pharma (P) Ltd. A process for preparation of iloperidone and amorphous co- precipitate of iloperidone with pharmaceutically acceptable excipient
DE102011051308A1 (de) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Herstellungsverfahren und Arzneiform
MX2014001556A (es) 2011-08-12 2014-03-31 Boehringer Ingelheim Vetmed Composicion farmaceutica de sabor enmascarado.
EP2604256B1 (en) * 2011-12-14 2016-04-13 Hexal AG Multi layer coatings
WO2013156163A1 (en) * 2012-04-19 2013-10-24 Glatt Ag Taste-masked pharmaceutical compositions containing diclofenac
HUE032635T2 (en) * 2012-09-19 2017-10-30 Taiho Pharmaceutical Co Ltd For oral administration of pharmaceutical compositions having improved elution and / or absorbance
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
SG11201505587YA (en) 2013-01-23 2015-08-28 Aldeyra Therapeutics Inc Toxic aldehyde related diseases and treatment
JP6328146B2 (ja) 2013-02-01 2018-05-23 グリアロジクス・インコーポレイテッドＧｌｉａｌｏｇｉｘ， Ｉｎｃ． 神経変性およびその他の疾患の治療用組成物および方法
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
AU2014228990B2 (en) 2013-03-15 2017-02-02 Aprecia Pharmaceuticals LLC Rapid disperse dosage form containing levetiracetam
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2938699A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion
US9616029B2 (en) 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3169331A4 (en) * 2014-07-17 2018-01-17 Jerome J. Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
AU2016311158A1 (en) 2015-08-21 2018-04-05 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
RU2760304C2 (ru) 2016-04-08 2021-11-23 Серено Сайентифик Аб Фармацевтические составы с отсроченным высвобождением, содержащие вальпроевую кислоту, и их применение
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018055615A1 (en) * 2016-09-22 2018-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Injectable implants
JP2020508350A (ja) * 2017-02-21 2020-03-19 アイシーオー セラピューティクス インコーポレイテッド アンホテリシンｂの固体経口製剤
MX2020003425A (es) 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Tratamiento de trastornos inflamatorios.
AU2019226030B2 (en) * 2018-02-21 2025-02-20 Aron H. BLAESI Expanding structured dosage form
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
EP3813831B1 (en) * 2018-09-21 2023-03-22 Amneal Complex Products Research LLC Extended release compositions comprising trihexyphenidyl
US20210393588A1 (en) * 2018-11-02 2021-12-23 Zenvision Pharma Llp Ready to use intravenous infusion of brivaracetam or salt thereof
US10824822B2 (en) * 2019-02-05 2020-11-03 International Business Machines Corporation Magnetic tracking for medicine management
US10679018B1 (en) 2019-02-05 2020-06-09 International Business Machines Corporation Magnetic tracking for medicine management
JP7706758B2 (ja) 2019-03-26 2025-07-14 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3175856A1 (en) * 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
CN113350309B (zh) * 2021-08-09 2021-11-12 北京五和博澳药业股份有限公司 一种难溶性药物渗透泵控释片剂及其制备方法
US11648207B1 (en) * 2021-12-15 2023-05-16 Intas Pharmaceuticals Ltd. Extended release pharmaceutical composition of Clozapine
US12303604B1 (en) * 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
JP3158435B2 (ja) * 1989-10-26 2001-04-23 日本新薬株式会社 徐放性製剤
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
JPH08208476A (ja) * 1995-02-01 1996-08-13 Kanebo Ltd ニフェジピン含有持続性製剤
DE69733476T2 (de) 1996-06-14 2006-03-23 Kyowa Hakko Kogyo Co., Ltd. Im munde schnellzerfallende tablette
DK1126826T6 (en) * 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
JP2000191519A (ja) * 1998-12-25 2000-07-11 Nippon Kayaku Co Ltd 薬効成分の不快な官能的性質が隠蔽された速放性粒状物
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500454B1 (en) 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
JP5062871B2 (ja) * 2003-05-13 2012-10-31 東和薬品株式会社 苦味を低減した口腔内崩壊錠剤
DE04801160T1 (de) * 2003-12-01 2007-08-09 Lifecycle Pharma A/S Pharmazeutische zusammensetzungen mit lercanidipin
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
US20060165788A1 (en) 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
ES2953390T3 (es) 2006-08-31 2023-11-10 Adare Pharmaceuticals Inc Sistemas de administración de fármacos que comprenden disoluciones sólidas de fármacos débilmente básicos

Also Published As

Publication number Publication date
EP2056792A4 (en) 2013-04-24
JP2010502645A (ja) 2010-01-28
CA2661683C (en) 2015-11-24
BRPI0716196A2 (pt) 2013-11-12
CA2661683A1 (en) 2008-03-06
MX2009002166A (es) 2009-03-12
AU2007289235A1 (en) 2008-03-06
IL197204A0 (en) 2009-12-24
US20080069878A1 (en) 2008-03-20
WO2008027993A2 (en) 2008-03-06
US10864166B2 (en) 2020-12-15
US20140050797A1 (en) 2014-02-20
RU2009111588A (ru) 2010-10-10
NZ575171A (en) 2012-04-27
ES2953390T3 (es) 2023-11-10
US20210046015A1 (en) 2021-02-18
JP2013199488A (ja) 2013-10-03
EP2056792B1 (en) 2023-06-07
EP2056792A2 (en) 2009-05-13
JP5913207B2 (ja) 2016-04-27
US12151028B2 (en) 2024-11-26
JP5513113B2 (ja) 2014-06-04
RU2434630C2 (ru) 2011-11-27
KR20140114887A (ko) 2014-09-29
KR20090057410A (ko) 2009-06-05
WO2008027993A3 (en) 2008-09-12
KR101468053B1 (ko) 2014-12-02

Similar Documents

Publication Publication Date Title
MX370905B (es) Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.
WO2008011595A3 (en) Hydrophobic abuse deterrent delivery system
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
UA91376C2 (ru) Рецептура с контролируемым высвобождением
MX2011006578A (es) Formulaciones farmaceuticas de liberacion prolongada.
WO2008017867A3 (en) Antiretroviral solid oral composition with at least one water insoluble polymer
AU2007211091A8 (en) Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
MX2009004871A (es) Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
BRPI0717509B8 (pt) sistema de liberação controlada para aplicação nasal de neurotransmissores
WO2008105773A3 (en) System for targeted delivery of therapeutic agents
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
MX2009004861A (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
MX2009003092A (es) Composiciones y metodos para suministro de farmaco dirigido a ph.
WO2013018050A3 (en) Dissolution enhanced controlled drug delivery system for poorly water soluble drugs
EP2231192A4 (en) DRUG DISPENSING SYSTEM FOR THE ADMINISTRATION OF A WATER-SOLUBLE, CATIONIC AND AMPHIPHILIC PHARMACEUTICAL ACTIVE SUBSTANCE
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
WO2006060325A3 (en) Coated drug delivery formulations
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
HK1128633A (en) Drug delivery systems comprising solid solutions of weakly basic drugs
ZA202003904B (en) Drug delivery system